Jagsonpal Pharma Q4FY26: Revenue Up 10% to ₹64.2 Cr, PAT Up 31% to ₹8.8 Cr; ₹40 Cr Buyback Approved
Jagsonpal Pharmaceuticals reported Q4 FY26 revenue of ₹64.2 Cr, up 10%, and PAT of ₹8.8 Cr, up 31%. FY26 revenue was ₹287.2 Cr, with PAT at ₹44.6 Cr, up 19%. The company proposed a 200% dividend and approved a ₹40 Cr buyback at ₹250 per share. Cash position stands at ₹190.7 Cr.
The announcement includes significant positive financial results, a substantial dividend increase, and a share buyback program, all of which are material events likely to impact investor sentiment and the company's stock price.
The company reported strong year-on-year growth in revenue and profit for Q4 and FY26. The proposed dividend increase and share buyback reflect confidence in future performance and a commitment to shareholder value.
Jagsonpal Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. For Q4 FY26, the company reported a revenue of ₹642 million (₹64.2 crore), a 9.6% increase year-on-year, and Profit After Tax (PAT) of ₹88 million (₹8.8 crore), up 31% YoY. Operating EBITDA stood at ₹106 million (₹10.6 crore) with a margin of 16.4%.
For the full fiscal year FY26, revenue grew by 6.9% to ₹2,872 million (₹287.2 crore), while Operating EBITDA was ₹609 million (₹60.9 crore) with a margin of 21.2%. PAT for FY26 increased by 19% to ₹446 million (₹44.6 crore).
The company's board has recommended a higher dividend distribution of 200% (including a 75% special dividend), resulting in a total cash outlay of approximately ₹262 million (₹26.2 crore) to shareholders. Additionally, the board has approved a buyback of up to 16 lakh equity shares at ₹250 per share, with a total outlay of ₹40 crore. Promoters will not participate in this buyback. This move is expected to improve ROCE from 22.0% to 25.7% and ROE from 16.2% to 18.9%.
The company's cash position as of March 31, 2026, was robust at ₹1,907 million (₹190.7 crore). Manish Gupta, Managing Director and CEO, highlighted that Jagsonpal's Q4 revenue growth of 10% outpaced the industry's IPM growth of 8.6%, with their top 10 brands contributing approximately 58% of revenues. He expressed confidence in future growth, driven by organic expansion, new product launches, and potential value-accretive inorganic opportunities.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.